OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

CEO received an award of 93K ALKS derivative securities | OQRO

Home
Insider trades
Alkermes plc
CEO received an award of 93K ALKS derivative securities

Insider trades

Insider trade

CEO received an award of 93K ALKS derivative securities

Traded Aug 5, 2026 · Filed Aug 8, 2026

ALKAlkermes plcALKS

93K
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Aug 5, 2026
Reporting period: Not applicable
Filed with the SEC: Aug 8, 2026

CEOGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001520262-26-000113
Filed / recorded

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Aug 8, 2026, 1:17 AM UTC

Added to OQRO

Oct 6, 2026, 9:54 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

Alkermes plc.

Issuer CIK

1520262

Ticker

ALKS

Reporting person

Blair Curtis Jackson

Relationship

Director, Officer

Officer title

President & CEO, Alkermes plc

Security

Employee Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Aug 5, 2026

Transaction code

Shares / units

93,229

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

93,229

Ownership form

Direct

Amendment

Footnotes from the filing

This award was granted in connection with the reporting person's appointment as President and Chief Executive Officer.
Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 8/5/2027.

Around the same time

David Joseph Gaffin (EVP, CLO, Alkermes, Inc.) sold ~$98K of Alkermes plc

Scheduled in advanceFiled 5w ago

Craig C. HopkinsonEVP R&D, Chief Medical Officer

Filed 5w ago

5,000Shares · @ $24.59

Traded Sep 1 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Craig C. Hopkinson (EVP R&D, Chief Medical Officer) sold ~$423K of Alkermes plc

Scheduled in advanceFiled 5w ago